A critical clue towards this goal was the detection of a recurrent MYB-NFIB fusion transcript in a subset of ACC tumors, however there are numerous obstacles preventing the direct targeting of a nuclear transcription factors, such as MYB, with pharmacological or biological agents. This evidence concerns the gene MYB and adrenal cortex carcinoma.